SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001739614-23-000063
Filing Date
2023-08-29
Accepted
2023-08-29 09:03:10
Documents
15
Period of Report
2023-08-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inhibrx-20230828.htm   iXBRL 8-K 37136
2 EX-4.1 inhibrx-ex41formofprexfund.htm EX-4.1 103321
3 EX-10.1 inhibrx-ex101formofsecurit.htm EX-10.1 393296
4 EX-99.1 pressrelease-pipeaugust2023.htm EX-99.1 10270
  Complete submission text file 0001739614-23-000063.txt   767666

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inhibrx-20230828.xsd EX-101.SCH 1928
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inhibrx-20230828_lab.xml EX-101.LAB 24851
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inhibrx-20230828_pre.xml EX-101.PRE 13061
9 EXTRACTED XBRL INSTANCE DOCUMENT inhibrx-20230828_htm.xml XML 2821
Mailing Address 11025 N. TORREY PINES ROAD, SUITE 200 LA JOLLA CA 92037
Business Address 11025 N. TORREY PINES ROAD, SUITE 200 LA JOLLA CA 92037 (858) 795-4220
Inhibrx, Inc. (Filer) CIK: 0001739614 (see all company filings)

IRS No.: 824257312 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39452 | Film No.: 231218526
SIC: 2836 Biological Products, (No Diagnostic Substances)